Tag Archives: esrd
Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis.
Hemodialysis.com eInterview with:
Dr. Vasily Belozeroff
Amgen, Thousand Oaks, CA, USA
Hemodialysis.com: What are the main findings of the study?
Dr. Belozeroff: Our meta analysis of observational studies suggests that there is an association between high levels of parathyroid hormone, calcium, and phosphorus and increased mortality in dialysis patients. Findings were less consistent for low levels of these biomarkers.
Marie Benz, MD on Google+Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease.
Hemodialysis.com eInterview with Dr. Marie Briet
Department of Pharmacology and Institut National de la Santé et de la Recherche Médicale
U970-PARCC, Hôpital Européen Georges Pompidou,
Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
Ernesto L. Schiffrin, CM, MD, PhD, FRSC, FRCPC, FACP
Physician-in-Chief, Sir Mortimer B. Davis-Jewish General Hospital,
Canada Research Chair in Hypertension and Vascular Research
Lady Davis Institute for Medical Research
Professor and Vice-Chair (Research), Department of Medicine
McGill University.
Written Interview conducted with author by Editor Marie Benz, MD
Hemodialysis.com: What are the main findings of the study?
Dr. Briet: The main finding is that EPO induces an endothelial dysfunction of small resistance arteries isolated from subcutaneous biopsies performed in chronic kidney disease patients. Considering that small arteries are the key determinants of blood pressure levels, the endothelial dysfunction induced by EPO could contribute to the increase in blood pressure and CV events observed in large interventional trials.
Geographic Variation in Black–White Differences in End-of-Life Care for Patients with ESRD
Hemodialysis.com eInterview with
Bernadette Thomas MD
University of Washington
Department of Nephrology
Seattle, Washington
Written Interview conducted with author by Editor Marie Benz, MD
Hemodialysis.com: What are the major findings of your study?
Dr. Thomas: The major findings of the study are:
1. There are pronounced black-white differences in end-of-life outcomes among patients with ESRD.
2. These differences vary substantially across regions of the United States.
3. Geography plays a role in differences in end-of-life outcomes for both whites and blacks.
Disease Progression and Surgical Parathyroidectomy in the EVOLVE Trial
Hemodialysis.com eInterview with:
Patrick Parfrey, MD, FRCPC, FACP on behalf of the EVOLVE investigators
University Research Professor at Memorial University
St. John’s, Newfoundland and a staff nephrologist.
Dr. Parfrey is Associate Dean for Clinical Research, Research Chief of Eastern Health
Hemodialysis.com: What are the main findings of the study?
Dr. Parfrey: The EVOLVE trail enrolled 3883 patients with secondary hyperparathyroidism from 22 countries , randomly allocated them to the calcimimetic, cinacalcet ,or placebo, and followed them for up to 64 months. Parathyroidectomy was undertaken in patients with severe unremitting hyperparathyroidism: PTH level prior to surgery 2143 mg/dl in the cinacalcet group and 1873 in the placebo group.
Pilot Study of a Physician-Delivered Education Tool to Increase Patient Knowledge About CKD
Hemodialysis.com Authors’ eInterview
J.A. Wright Nunes, MD MPH
Assistant Professor
University of Michigan Health System
Department of Internal Medicine, Division of Nephrology
Kerri Cavanaugh, MD MHS
Assistant Professor of Medicine
Vanderbilt University Medical Center
Division of Nephrology
Center for Health Services Research Nashville, TN 37232-2372
Hemodialysis.com: What are the main findings of the study?
Answer: The main finding of the study was that a simple, efficient educational worksheet designed to facilitate patient-provider communication about kidney disease, increased patient knowledge in fundamental areas related to their kidney health.
We are also encouraged by the very positive response in patients who received the educational worksheet, as well as the providers who delivered the tool in practice.
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy – a meta-analysis of 11 randomized controlled trials involving 21,295 participants
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy – a meta-analysis of 11 randomized controlled trials involving 21,295 participants
Prof. Maciej Banach, MD, FNLA, FAHA, FESC, FASA, FRSPH
President, Polish Lipid Association
http://www.polishlipidassociation.com
Editor-in-chief, Archives of Medical Science
http://www.ArchivesofMedicalScience.com
Head, Department of Hypertension
Chair of Nephrology and Hypertension
Medical University of Lodz, Poland
E-mail: maciej.banach@umed.lodz.pl
Hemodialysis.com: What are the main findings of the study?
Dr. Banach: The use of statins in subjects with non-dialysis-dependent chronic kidney disease (CKD) resulted in a marked (statistically significant) reduction in death from all causes, cardiac causes, cardiovascular events and stroke. The use of statins in dialysis-dependent CKD patients resulted in a non‑significant effect on death from all causes and stroke, but had the effect of reducing death from cardiac causes and cardiovascular events (however the last two data were obtained on the very limited studies).
Influence of Wasting on Hyperparathyroidism in Black Diabetic Hemodialysis Patients
Hemodialysis.com Interview with Rapeepat Lekkham, MD
Nephrology Fellow,
Albert Einstein Medical Center,
Philadelphia, PA
Hemodialysis.com: What are the main findings of the study?
Dr. Lekkham: We conducted the retrospective study on hemodialysis patients who mainly (92.9%) were black and stratified by the absence or presence of wasting syndrome (which defined by serum albumin less than 3.8 g/dl, normalized protein nitrogen appearance (nPNA) less than 0.8 g/kg/day and BMI less than 23 kg/m2) and the association with secondary hyperparathyroidism. Compared to non-diabetic patients, our study found that diabetic patients had a higher mean serum iPTH. Also, serum iPTH was higher in all diabetic non-wasting subgroups patients as well. Other related parameters including mean serum phosphate, serum alkaline phosphatase, the requirement of cinacalcet, vitamin D analogues and phosphate binders were comparable in both groups.
Cost implications of switching from sevelamer to lanthanum carbonate within a bundled reimbursement scenario
Interview with Dr. Michael S Keith Shire Pharmaceuticals, Wayne, PA, USA
Hemodialysis.com: What are the main findings of the study?
Dr. Keith: The key finding from this post hoc analysis is that phosphate control was similar regardless of the prior sevelamer dose a patient received. Overall mean phosphate binder doses were SH 7703 mg/day and LC 2800 mg/day. Drug cost-savings were realized when applying clinically utilized doses of lanthanum carbonate (LC) 3000 mg/day ($26.46/day) and sevelamer hydrochloride (SH) from doses of 6400 mg/day ($29.68/day) and above. Cost savings were as high as $18/day when converting patients from SH 9600 mg/day to LC 3000 mg/day.
